Study could lead to new strategies for slowing the growth of glioblastoma

Gene Editing Services

Ubigene has modified over 5000 genes from more than 200 cell lines with our exclusive innovation CRISPR-U™ technology. At the same time, we already provide customers with high quality gene-editing tools for cell or animal research worldwide.

Stable Cell Lines

Knockout Cell Lines

Knockin Cell Lines

Overexpression Cell Lines

Knockdown Cell Lines

iPSC and ESC Gene editing

Cloning Services

Knockout Plasmid

Point Mutation Plasmid

Knockin Plasmid

Overexpression Plasmid

Knockdown Plasmid

Virus Packaging

Lentivirus Packaging

Adenovirus Packaging

Adeno-associated Virus Packaging

CRISPR Library

CRISPR Library In-stock

Customized CRISPR Library

CRISPR Library Screening

Microbe

Gene-editing E.coli

Gene-editing Salmonella

Gene-editing P. aeruginosa

Gene-editing S. aureus

Cell Assay

Cell Proliferation

Cell Migration and Invasion

Cell Cycle

Cell Apoptosis

Detection of Marker Protein Expression

Cytokine Secretion and Enzyme Activity Test

Cytotoxicity Test

EZ-editor™
Gene-editing Series Products

With 14 years of experience, Ubigene has exclusively innovated and developed 6 product lines, fullfilling all kinds of needs from researchers. Experiment process simplified, efficiency improved, achieving our aim of 'Make genome editing easier'!

Red Cotton™ gRNA Plasmid Bank

Regular Plasmid

Lentiviral Plasmid

EZ-editor™ Culture Medium

Transfection Culture Medium

Cell Monoclonal Culture Medium

EZ-Stem™ Cell Culture Medium

EZ-cryo™ Cell Freezing Medium

Knockout-cell-lysate

KO cell lysates (clone)

KO cell lysates (pool)

EZ-editor™ Cell Line

KO Cell Lines

Wild-type Cell Lines

Cas9 Stable Cell Lines

Luciferase Stable Cell Lines

EGFP Stable Cell Lines

EZ-editor™ Kits

Monoclone Genotype Validation Kit (extraction free)

EZ-editor™ Gene Knockout kit

Mouse Genotyping Kit

Lentiviral Packaging Kit

Lentivirus

IVD positive controls

Point Mutation gDNA/Cell Line

Red Cotton Gene knockout Project

Ubigene exclusive KO Cell Line Bank, over 5000 KO cell lines, covering thousands of genes from 8 popular signaling pathways and nearly 100 diseases.

Red Cotton CRISPR Gene Editing Designer

Gene Editing Cell Designer

Gene Editing Point Mutation Designer

Gene Editing Microbe Designer

Gene Editing Tool Kit

Red Cotton Gene knockout Project

Location：Home > About Us > Blogs >

Contact us✖

* Name：

Institution：

* Project Description：

* How would you like us to contact you?

* E-mail：

Phone：

WhatsAPP：

FaceBook Messenger：

Our Solution Specialists will contact you within 2 business days. Of course, you can also tell us when you would like to be contacted:

Select：

Study could lead to new strategies for slowing the growth of glioblastoma

Researchers are hopeful that new strategies could emerge for slowing the growth and recurrence of the most common primary brain cancer in adults, glioblastoma, based on the results of a study published today in Cancer Research.

Research led by Toronto's St. Michael's Hospital and The Hospital for Sick Children (SickKids) suggests the protein ID1 is critical to tumor initiation and growth and also impacts the disease's response to chemotherapy. ID1 is a protein that keeps other genes from being activated or repressed by binding to their activators or inhibitors. In this work, scientists found that ID1 helps maintain cancer stem cells in glioblastoma, making them less susceptible to treatment.

Researchers found that when they "turned off" the protein ID1 in lab models and human cells using CRISPR technology or a drug that is traditionally used to treat psychosis and Tourette's syndrome - pimozide - glioblastoma tumors slowed down. The team also found that turning off the protein altogether helped tumors become less resistant to chemotherapy.

Glioblastoma is an aggressive form of brain cancer, representing 15 per cent of all primary brain tumors, and is often difficult to treat. Therapy generally involves the combination of several approaches to control the disease, but there is currently no cure. The diagnoses of the late Tragically Hip singer Gord Downie and U.S. Sen. John McCain have raised the profile of glioblastoma in recent years.

"The average survival rate for glioblastoma is less than two years and we unfortunately don't have too many options to offer these patients," said Dr. Das, who is also a neurosurgeon at St. Michael's.

"Our findings suggest that we may be able to enhance the effectiveness of therapies we already have, such as chemotherapy, as opposed to taking many years to create entirely new therapies."

In lab models, researchers found that inhibiting ID1 slows the progression of tumors in glioblastoma, breast adenocarcinoma and melanoma. In human tissue, they found that the protein caused cells to be more resistant to chemotherapy treatment in glioblastoma. Turning off this protein using the medication pimozide increased overall survival and caused glioblastoma tumors to recur less frequently, progress less and grow more slowly.

"Targeting the protein with medication may present a novel and potentially promising strategy for patients with glioblastoma," Dr. Das said.

The next steps for this research, Dr. Das explained, are to look at the development of new inhibiting medications for ID1 and commence a trial to ensure that the targeting is effective.